The demand for API antibiotics will continue to increase at a steady rate between 2021 and 2031. It is often the first choice for treating infections. According to a new study by Future Market Insights (IMF), the antibiotics API market is expected to exceed US$8.1 billion in 2021. Antibiotics are intended to make medical procedures much safer.
Any surgery or chronic disease is susceptible to bacterial infection, which puts the patient at increased risk. Rising incidence of infections such as tuberculosis, pneumonia, blood poisoning, gonorrhea, and foodborne illnesses would drive an increase in the demand for antibiotics which is expected to drive the antibiotic API market.
Click for sample report: https://www.futuremarketinsights.com/reports/sample/rep-gb-13025
According to the World Health Organization (WHO), pneumonia caused by bacteria can be treated with antibiotics. Around 15% of child deaths were due to pneumonia in 2017. According to 2018 UNICEF data, globally there are approximately 1,400 cases of pneumonia per 100,000 children, with the highest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children)
The COVID-19 pandemic is believed to have a negative impact on the Antibiotics API market. Some of the major biotechnology companies, research institutes and pharmaceutical companies are named in collaboration to deal with the situation. This shifted their focus and resources from manufacturing other drugs to coronavirus vaccines. Shortage of various APIs and restricted hospital visits due to increasing number of COVID-19 patients has shaken the global antibiotic API market.
In terms of APIs, the penicillin-based antibiotics segment dominated the API antibiotics market with a market share of 51.1% in 2021 owing to the growing demand and adoption of penicillin as an antibiotic of first line to treat many bacterial infections. Pharmaceutical companies are expected to dominate the end user segment. They are expected to hold over 77% of the market and remain dominant throughout the forecast period.
Key Insights from Antibiotic API Market Research
- The global antibiotic API market is estimated to be worth US$8.01 billion in 2020, with the market expected to grow at a CAGR of 3.1% during the forecast period (2020-2030)
- The United States holds over 92.1% of the North American market, but Canada is expected to see a faster CAGR
- UK market to show steady annual growth of 2.1% in 2021
- Demand from Germany and France will grow at a positive rate throughout the forecast period
- In East Asia, China will become a key market, while Japan and South Korea will continue to show stable demand
“The increasing prevalence of bacterial diseases, the extreme use of antibiotics and the increase in investments in R&D are is expected to drive the growth of the Antibiotics API market. IMF analyst says
Increasing investment in the R&D sector to develop advanced molecules is the major factor expected to drive the growth of the antibiotic API market.
For example, Sandoz, the biosimilars and generics division of Novartis, is being jointly invested with the Austrian federal government to improve the long-term future of integrated antibiotic manufacturing in Europe.
Click here to BUY the report: https://www.futuremarketinsights.com/checkout/13025
Antibiotics API key players enter into strategic alliance
The major players are focusing on increasing acquisitions at the regional level. Acquisitions strengthen the business with products and increase the company’s portfolio. The company acquires to own well-established products and solutions that expect to represent a good source of revenue for the acquirer. It also allows the company to enter new emerging markets as well as improve existing markets.
For example, in August 2019, Nanjing Dorra Pharmaceutical Technology collaborated with Meitheal Pharmaceuticals, the fully integrated generic injectables company, to increase manufacturing capacity of active pharmaceutical ingredients in the US region. The collaboration allowed Meitheal Pharmaceuticals to invest in Nanjing Dorra Pharmaceutical technology.
The global antibiotic API market is expected to expand its reach over the forecast period, owing to the growing prevalence of various bacterial diseases and growing investment in R&D. The antibiotics market is highly competitive and consists of several major players. Pharmaceutical companies are focusing more on outsourcing manufacturing of API antibiotics due to the involvement of high capital investments in establishing manufacturing units of API antibiotics.
The major market players covered by FMI are Sandoz International GmbH, Centrient Pharmaceuticals, CordenPharma International, ACS DOBFAR SPA, Nanjing Dorra Pharmaceutical Technology Co. Ltd., DAEWOONG PHARMACEUTICAL CO. LTD., Parabolic Drugs Ltd., Penam Laboratories Ltd., ASIATIC DRUGS & PHARMACEUTIQUES PVT. LTD., Fresenius Kabi, United Laboratories International Holdings Limited, Aurobindo Pharma Limited, Unimark Remedies Ltd., Savior Lifetec, Shenzhen Haibin Pharmaceutical Co., Ltd., Sterile India Pvt. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd. and Kyongbo Pharm, consolidating their positions through mergers, acquisitions and new product launches.
Click on the link for the table of contents of this report: https://www.futuremarketinsights.com/reports/antibiotics-active-pharmaceutical-ingredient-api-market/table-of-content
About Future Market Insights Healthcare Division
Future Market Insights helps businesses, governments, investors, and related audiences in the healthcare sector identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technological evolution, and other issues crucial to achieving lasting success. Our unique approach to gathering market intelligence enables you to design innovation-driven trajectories for your business. Learn more about our industry coverage here
About Future Market Insights (IMF)
Future Market Insights (FMI) is a leading provider of market information and advisory services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, USA and India. FMI’s latest market research reports and industry analysis help businesses meet challenges and make critical decisions with confidence and clarity amidst fierce competition. Our custom and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of analysts led by FMI experts continuously monitor emerging trends and events across a wide range of industries to ensure our clients are prepared for the changing needs of their consumers.
Future Market Outlook
Unit No.: AU-01-H Gold Tower (AU), Parcel No.: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For sales inquiries: [email protected]
For media inquiries: [email protected]